# Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

> **NCT03983226** · PHASE2 · RECRUITING · sponsor: **Shanghai Gynecologic Oncology Group** · enrollment: 167 (estimated)

## Conditions studied

- Ovarian Cancer Recurrent
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **PROCEDURE:** Surgery
- **DRUG:** carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03983226
- **Lead sponsor:** Shanghai Gynecologic Oncology Group
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-18
- **Primary completion:** 2025-06
- **Final completion:** 2026-12
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2022-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983226, "Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03983226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*